Medical Device

Abbott announced today it is teaming up with Eliud Kipchoge, who is considered the world's fastest marathon runner, and the NN Running Team to support their athletic performance training program. Kipchoge and three NN Running Team members are training with Abbott's Libre Sense Glucose Sport Biosensor to monitor their glucose levels to help them achieve optimal athletic performance. The NN Mission Marathon, a ...

- Abbott (NYSE: ABT) announced today it is teaming up with Eliud Kipchoge, who is considered the world's fastest marathon runner, and the NN Running Team to support their athletic performance training program. Kipchoge and three NN Running Team members are training with Abbott's Libre Sense Glucose Sport Biosensor to monitor their glucose levels to help them achieve optimal athletic performance. The NN Mission Marathon, a qualifying race for the Olympic Games, in Enschede, the Netherlands on April 18 will be the first time Kipchoge and the NN Running Team will use Abbott's biosensor in a competitive marathon.

Eliud Kipchoge is training with Abbott's Libre Sense to monitor his glucose levels to help him achieve optimal athletic performance.

"Using Abbott's Libre Sense has transformed my training program. I am learning how my glucose levels relate to my running performance and have already started to see how quickly small adjustments can make a big difference," said Eliud Kipchoge, the world's fastest marathon runner. "I am honored to work on this project, which hopefully will help athletes around the world to better understand the relationship between nutrition and performance to help them improve."

Kipchoge is celebrated as the greatest marathon runner in history as a three-time Olympic medal winner and the first person in history to run a marathon in under two hours. To maintain elite performance, Kipchoge and the NN Running Team continually seek to innovate across all aspects of their training program, evaluating everything from race planning, nutrition and hydration to clothing and footwear. As the first product of its kind, Abbott's biosensor empowers the runners to tap into real-time molecular data to monitor their glucose levels and help them design personalized nutrition plans.

"We've utilized our breakthrough sensing technology to help world-class athletes like Eliud and everyday athletes alike live up to their optimal potential," said Duncan Williams , divisional vice president, Biosensor Technology, Abbott. "Libre Sense will help make glucose monitoring commonplace in athletic performance training and enable athletes to fuel their peak performance."

Abbott's Libre Sense, CE Marked in September 2020 , is an over-the-counter product made available in Europe that is designed to provide continuous glucose monitoring via a mobile app iii and wrist readers iv to athletes. Athletes wear the small round biosensor (approximately the size of a two Euro coin) on the back of their upper arm. Worn for up to 14 days, the biosensor provides real-time glucose values through a mobile app developed by Supersapiens, a sports technology company focused on improving athletic performance. Abbott's biosensor and Supersapiens app are designed to help athletes understand the efficacy of their nutrition choices in training and competition.

Abbott is providing Kipchoge and the NN Running Team members with Abbott's biosensors for training, as well as collaborating to develop personalized insights into their athletic performance. Kipchoge and the NN Running Team will provide key learnings, share their experiences and educate athletes worldwide to better understand the link between nutrition and performance.

To prepare for the NN Mission Marathon, their last competitive marathon before the Olympic Games, Eliud and the NN Running Team have been training in Kenya using Libre Sense for the past month.

"After training with Abbott's biosensor, we've been able to quickly develop new insights into high-performance, endurance training nutrition and hydration. For example, we are exploring a shift in timing of pre-race and race-time carbohydrate fueling to net maximum benefits," said Valentijn Trouw, performance director of NN Running Team and Global Sports Communications. "Abbott's biosensor enables us to build personalized nutrition plans based on glucose data in order to deliver peak athletic performance and a competitive advantage. The NN Mission Marathon will be an excellent opportunity to show how important glucose insights can make a real difference in performance."

To see Kipchoge and the NN Running Teams training sessions in Kenya with the Abbott biosensor, click here .

About Abbott Libre Sense Glucose Sport System
The Abbott Libre Sense Glucose Sport Biosensor is intended for athletes (aged 16+ years) to measure glucose. Athletes are defined as individuals who perform exercise and train with the purpose of improving fueling and performance. The biosensor allows athletes to correlate their glucose levels and their athletic performance. The biosensor is not intended for use in the diagnosis, treatment, or monitoring of a disease.

The product is available across eight European countries: Austria , France , Germany , Ireland , Italy , Luxembourg , Switzerland and the United Kingdom .

For more information about Abbott's biosensor, visit LibreSense.com . For more information about the app, visit Supersapiens.com .

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

i Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
ii The biosensor is the world's first continuous glucose biosensor specifically designed for athletes; data on file, Abbott.
iii Biosensor is designed to work with compatible partner mobile apps.
iv The biosensor is designed to automatically stream glucose data every minute, via Bluetooth ® wireless technology, and it is designed to work with compatible mobile apps and wrist readers (wrist readers are currently in development).

Abbott Logo (PRNewsFoto/Abbott)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/worlds-fastest-marathoner-eliud-kipchoge-uses-abbotts-libre-sense-at-nn-mission-marathon-qualifier-race-for-the-olympic-games-301266487.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

Bausch Health Companies Inc. Announces First-Quarter 2022 Results

  • First-Quarter 2022 Financial Results
    • Revenues of $1.918 Billion
    • GAAP Net Loss of $69 Million
    • Adjusted EBITDA (non-GAAP) 1 of $732 Million
  • Bausch + Lomb Commences Trading Under "BLCO" Ticker Following IPO 2
  • Updates Full-Year Revenue and Adjusted EBITDA (non-GAAP) 1 Guidance Ranges

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its first-quarter 2022 financial results.

"Our organic 3 growth in the first quarter of 2022 was stable compared to the same quarter last year, despite incremental macro pressures and a challenging supply chain environment," said Thomas J. Appio , incoming chief executive officer ("CEO"), Bausch Health. "Following the closing of the initial public offering of the Bausch + Lomb eye health business later today, we will operate as two companies, which enables Bausch Health to increase its focus on accelerating growth with strategic commercial investments and expanding our pipeline with innovative products that improve the quality of life for patients around the world."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics

Broad range RNA integrity and quality analysis kit for SCIEX capillary electrophoresis instruments launches at TIDES 2022

At TIDES 2022, SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches the RNA 9000 Purity & Integrity kit, for the BioPhase 8800 system and PA 800 Plus system.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health of America

Premier Health of America: Modernizing Healthcare Staffing with Automated, On-Demand Services

Premier Health of America (TSXV:PHA) has launched its campaign on the Investing News Network's Medical Device channel.

Premier Health of America (TSXV:PHA) is a modern healthcare staffing platform that gives healthcare workers and facilities access to leading technologies to finally create a truly flexible workforce.

The company’s mobile app technology, PSweb, is at the core of its operations, and the app has been live for over a decade. Artificial intelligence (AI) and big data power the app, delivering a genuinely automated process to healthcare facilities and professionals. The platform serves the healthcare needs of governments, corporations, and individuals. A healthcare facility simply posts an open shift and desired skill set, and providers around the country can claim it.

Keep reading...Show less

Bausch Health Announces Thomas J. Appio As Chief Executive Officer

Bausch Health Companies Inc. (NYSETSX: BHC) (Bausch Health) today announced its full leadership team and Board of Directors, including Chief Executive Officer (CEO) Thomas J. Appio . 1 Upon completion of the initial public offering (IPO) of the Bausch + Lomb eye health business, 2 former CEO Joseph C. Papa will assume the role of chairman and CEO of Bausch + Lomb.

"It is an honor and privilege to lead Bausch Health at this pivotal time in its history, and I am excited for our future," said Mr. Appio. "We are a global specialty pharmaceutical company with deep expertise in gastroenterology, hepatology, neurology, dermatology and international pharmaceuticals serving patients for more than 60 years."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Present at BofA Securities 2022 Healthcare Conference

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. (EDT).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bausch + Lomb Corporation Announces Pricing of IPO

Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced the pricing of its initial public offering ("IPO") of 35,000,000 common shares at a public offering price of $18.00 per share. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") is offering all of the common shares, and Bausch + Lomb will not receive any of the proceeds from the IPO. The Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 5,250,000 common shares of Bausch + Lomb to cover over-allotments, if any, at the initial public offering price, less underwriting commissions.

The common shares have been approved for listing on the New York Stock Exchange ("NYSE") and conditionally approved for listing on the Toronto Stock Exchange ("TSX"). The common shares are expected to begin trading on the NYSE and on an "if, as and when issued basis" on the TSX on May 6, 2022 , in each case under the ticker symbol "BLCO." The offering is expected to close on May 10, 2022 , subject to customary closing conditions.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×